Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
Figure 10.1 Survival estimates from diagnosis of primary myelofibrosis patients who become intermediate-2 and high-risk International Prognostic Score System (IPSS) with a blast cell count <10% at any time of…